Selling Obesity Drugs to Americans Shouldn't Be This HardBy
The 79 million obese adults in the U.S. should be a marketing dream for the makers of anti-obesity drugs, and now Contrave, the latest treatment to receive approval from the Food and Drug Administration, will try to win over a population in which more than 1 in 3 adults are obese. Yet sales have been weak for the prescription drugs already available, Qsymia and Belviq, both approved in 2012. Why has it been so difficult to pitch pharmaceutical weight loss to an overweight nation?
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Billionaire Tom Barrack Throws Harvey Weinstein a Lifeline
- Everything Is Crazy and the Markets Aren’t Freaking Out
- Facebook Is Looking for Employees With National Security Clearances
- London House Prices Fall Most Since Financial Crisis
- Kushners’ Control of Family’s NYC Crown Jewel Is Now in Jeopardy